Market closedNon-fractional
X4 Pharmaceuticals/XFOR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About X4 Pharmaceuticals
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Ticker
XFOR
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Boston, United States
Employees
116
Website
www.x4pharma.com
XFOR Metrics
BasicAdvanced
$145M
Market cap
-
P/E ratio
-$0.67
EPS
0.51
Beta
-
Dividend rate
Price and volume
Market cap
$145M
Beta
0.51
Financial strength
Current ratio
3.71
Quick ratio
3.465
Long term debt to equity
5,515.637
Total debt to equity
5,625
Interest coverage (TTM)
-17.66%
Management effectiveness
Return on assets (TTM)
-61.03%
Return on equity (TTM)
-489.12%
Valuation
Price to book
140.16
Price to tangible book (TTM)
-8.9
Price to free cash flow (TTM)
-1.595
Growth
Earnings per share change (TTM)
-35.86%
3-year earnings per share growth (CAGR)
-44.04%
What the Analysts think about XFOR
Analyst Ratings
Majority rating from 6 analysts.
XFOR Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$52M
170.68%
Profit margin
0.00%
NaN%
XFOR Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.33
-$0.01
-$0.10
-$0.26
-
Expected
-$0.16
-$0.15
-$0.15
-$0.16
$0.01
Surprise
102.04%
-93.28%
-34.58%
59.65%
-
XFOR News
AllArticlesVideos
X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data
Seeking Alpha·3 weeks ago
X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial
GlobeNewsWire·4 weeks ago
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for X4 Pharmaceuticals stock?
X4 Pharmaceuticals (XFOR) has a market cap of $145M as of July 27, 2024.
What is the P/E ratio for X4 Pharmaceuticals stock?
The price to earnings (P/E) ratio for X4 Pharmaceuticals (XFOR) stock is 0 as of July 27, 2024.
Does X4 Pharmaceuticals stock pay dividends?
No, X4 Pharmaceuticals (XFOR) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next X4 Pharmaceuticals dividend payment date?
X4 Pharmaceuticals (XFOR) stock does not pay dividends to its shareholders.
What is the beta indicator for X4 Pharmaceuticals?
X4 Pharmaceuticals (XFOR) has a beta rating of 0.51. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell X4 Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.